{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T03:11:51Z","timestamp":1794971511741,"version":"4.9.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.vaccine.2022.12.069","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T04:36:12Z","timestamp":1673238972000},"page":"1859-1863","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Safety of co-administration of mRNA COVID-19 and seasonal inactivated influenza vaccines in the vaccine adverse event reporting system (VAERS) during July 1, 2021\u2013June 30, 2022"],"prefix":"10.1016","volume":"41","author":[{"given":"Pedro L.","family":"Moro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bicheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Ennulat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"McVey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Woody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige","family":"Marquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"50","key":"10.1016\/j.vaccine.2022.12.069_b0005","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.15585\/mmwr.mm6950e2","article-title":"The Advisory Committee on Immunization Practices\u2019 interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine\u2014United States, December 2020","volume":"69","author":"Oliver","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5152","key":"10.1016\/j.vaccine.2022.12.069_b0010","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.15585\/mmwr.mm695152e1","article-title":"The Advisory Committee on Immunization Practices\u2019 interim recommendation for use of Moderna COVID-19 vaccine\u2014United States, December 2020","volume":"69","author":"Oliver","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2022.12.069_b0015","doi-asserted-by":"crossref","unstructured":"Fleming-Dutra KE, Wallace M, Moulia DL, et al. Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months\u20135 Years \u2014 United States, June 2022. MMWR Morb Mortal Wkly Rep 2022;71:859\u2013868. DOI:http:\/\/dx.doi.org\/10.15585\/mmwr.mm7126e2.","DOI":"10.15585\/mmwr.mm7126e2"},{"key":"10.1016\/j.vaccine.2022.12.069_b0020","doi-asserted-by":"crossref","unstructured":"Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose. FDA News Release. August 31, 2022. Accessed October 10, 2022 https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use.","DOI":"10.47287\/cen-09931-buscon1"},{"key":"10.1016\/j.vaccine.2022.12.069_b0025","unstructured":"CDC Expands Updated COVID-19 Vaccines to Include Children Ages 5 Through 11. Accessed at https:\/\/www.cdc.gov\/media\/releases\/2022\/s1012-COVID-19-Vaccines.html."},{"key":"10.1016\/j.vaccine.2022.12.069_b0030","unstructured":"Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use."},{"key":"10.1016\/j.vaccine.2022.12.069_b0035","unstructured":"Seasonal Influenza Vaccination Resources for Health Professionals. https:\/\/www.cdc.gov\/flu\/professionals\/vaccination\/index.htm."},{"key":"10.1016\/j.vaccine.2022.12.069_b0040","unstructured":"CDC. Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States. https:\/\/www.cdc.gov\/vaccines\/COVID-19\/clinical-considerations\/interim-considerations-us.html#:\u223c:text=COVID%2D19%20vaccination%20is%20recommended,younger%20than%20age%206%20months."},{"issue":"7","key":"10.1016\/j.vaccine.2022.12.069_b0045","doi-asserted-by":"crossref","first-page":"e2222241","DOI":"10.1001\/jamanetworkopen.2022.22241","article-title":"Reactogenicity of Simultaneous COVID-19 mRNA Booster and Influenza Vaccination in the US","volume":"5","author":"Hause","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"36","key":"10.1016\/j.vaccine.2022.12.069_b0050","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.12.069_b0055","unstructured":"Medical dictionary for regulatory activities. https:\/\/www.meddra.org\/."},{"key":"10.1016\/j.vaccine.2022.12.069_b0060","unstructured":"CFR Part 600.80. Postmarketing reporting of adverse experiences. Fed Regist 1997;7:52252\u201353."},{"key":"10.1016\/j.vaccine.2022.12.069_b0065","unstructured":"Vaccine Adverse Event Reporting System. https:\/\/vaers.hhs.gov\/faq.html."},{"issue":"31","key":"10.1016\/j.vaccine.2022.12.069_b0070","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1016\/j.vaccine.2007.02.064","article-title":"Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"25","author":"R\u00fcggeberg","year":"2007","journal-title":"Vaccine"},{"issue":"15","key":"10.1016\/j.vaccine.2022.12.069_b0075","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.vaccine.2016.05.023","article-title":"Facial nerve palsy including Bell's palsy: Case definitions and guidelines for collection, analysis, and presentation of immunisation safety data","volume":"35","author":"Rath","year":"2017","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2022.12.069_b0080","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","article-title":"Brighton Collaboration GBS Working Group Guillain-Barre syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"29","author":"Sejvar","year":"2011","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2022.12.069_b0085","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.2021.24110","article-title":"Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021","volume":"327","author":"Oster","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2022.12.069_b0090","doi-asserted-by":"crossref","unstructured":"Murphy SL, Kochanek KD, Xu JQ, Arias E. Mortality in the United States, 2020. NCHS Data Brief, no 427. Hyattsville, MD: National Center for Health Statistics. 2021. DOI: https:\/\/dx.doi.org\/10.15620\/cdc:112079.","DOI":"10.15620\/cdc:112079"},{"key":"10.1016\/j.vaccine.2022.12.069_b0095","doi-asserted-by":"crossref","unstructured":"McNeil MM, Gee J, Weintraub ES, Belongia EA, Lee GM, Glanz JM, et al. The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety. Vaccine. 2014 Sep 22;32(42):5390-8. doi: https:\/\/doi.org\/10.1016\/j.vaccine.2014.07.073. Epub 2014 Aug 6. PMID: 25108215; PMCID: PMC6727851.","DOI":"10.1016\/j.vaccine.2014.07.073"},{"issue":"16","key":"10.1016\/j.vaccine.2022.12.069_b0100","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1001\/jama.2021.16496","article-title":"Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barr\u00e9 Syndrome, February-July 2021","volume":"326","author":"Woo","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2022.12.069_b0105","doi-asserted-by":"crossref","unstructured":"See I, Su JR, Lale A, et al. US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 20JAMA. 2021;325(24):2448\u20132456. doi: https:\/\/doi.org\/10.1001\/jama.2021.7517.","DOI":"10.1001\/jama.2021.7517"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23000166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23000166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:23:20Z","timestamp":1759404200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23000166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0264410X23000166"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.12.069","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of co-administration of mRNA COVID-19 and seasonal inactivated influenza vaccines in the vaccine adverse event reporting system (VAERS) during July 1, 2021\u2013June 30, 2022","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.12.069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}